-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
What Kind Of Shareholders Hold The Majority In Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares?
What Kind Of Shareholders Hold The Majority In Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares?
The big shareholder groups in Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.
With a market capitalization of CN¥16b, Haisco Pharmaceutical Group is a decent size, so it is probably on the radar of institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions don't own many shares in the company. We can zoom in on the different ownership groups, to learn more about Haisco Pharmaceutical Group.
See our latest analysis for Haisco Pharmaceutical Group
SZSE:002653 Ownership Breakdown August 3rd 2022What Does The Institutional Ownership Tell Us About Haisco Pharmaceutical Group?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Institutions have a very small stake in Haisco Pharmaceutical Group. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. So if the company itself can improve over time, we may well see more institutional buyers in the future. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.
SZSE:002653 Earnings and Revenue Growth August 3rd 2022Hedge funds don't have many shares in Haisco Pharmaceutical Group. Looking at our data, we can see that the largest shareholder is the CEO Jun Min Wang with 38% of shares outstanding. For context, the second largest shareholder holds about 25% of the shares outstanding, followed by an ownership of 17% by the third-largest shareholder. Interestingly, the second-largest shareholder, Xiu Lian Fan is also Senior Key Executive, again, pointing towards strong insider ownership amongst the company's top shareholders.
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Haisco Pharmaceutical Group
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our information suggests that insiders own more than half of Haisco Pharmaceutical Group Co., Ltd.. This gives them effective control of the company. That means insiders have a very meaningful CN¥14b stake in this CN¥16b business. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if they have been selling down their stake.
General Public Ownership
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Haisco Pharmaceutical Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Haisco Pharmaceutical Group better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Haisco Pharmaceutical Group you should be aware of, and 2 of them shouldn't be ignored.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
海思科藥業集團股份有限公司(SZSE: 002653)的大股東集團對公司擁有控制權。機構通常擁有更成熟的公司的股份,而內部人士擁有相當一部分規模較小的公司的情況並不少見。我很想看到至少一點內部所有權。正如查理·芒格所說:“給我看激勵措施,我會告訴你結果。
海思科製藥集團的市值爲160億人民幣,規模不錯,因此可能受到機構投資者的關注。看看我們關於所有權集團的數據(見下文),機構似乎並不擁有該公司的太多股份。我們可以放大不同的所有權組,以瞭解有關海思科製藥集團的更多信息。
查看我們對海思科製藥集團的最新分析
SZSE: 002653 所有權明細 2022 年 8 月 3 日機構所有權告訴我們關於海思科藥業集團的哪些信息?
機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。
機構持有海思科製藥集團的股份很少。這表明該公司受到一些基金的關注,但目前它在專業投資者中並不是特別受歡迎。因此,如果公司本身能夠隨着時間的推移而有所改善,那麼將來我們很可能會看到更多的機構買家。當多個機構投資者想要購買股票時,我們經常會看到股價上漲。過去的收入軌跡(如下所示)可以預示未來的增長,但無法保證。
SZSE: 002653 2022年8月3日收益和收入增長對沖基金在海思科藥業集團的股份不多。從我們的數據來看,我們可以看到最大的股東是首席執行官王軍民,擁有38%的已發行股份。就背景而言,第二大股東持有約25%的已發行股份,其次是第三大股東持有17%的所有權。有趣的是,第二大股東範秀蓮也是高級主要執行官,這表明該公司主要股東擁有強大的內部所有權。
爲了使我們的研究更有趣,我們發現前兩名股東擁有公司的多數股權,這意味着他們足夠強大,足以影響公司的決策。
研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。
海思科藥業集團的內部所有權
不同國家對內部人士的定義可能略有不同,但董事會成員始終算在內。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。
當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。
我們的信息表明,內部人士擁有海思科藥業集團有限公司一半以上的股份。這使他們能夠有效控制公司。這意味着內部人士在這項160億元人民幣的業務中擁有非常有意義的140億元人民幣的股份。大多數人會認爲這是積極的,顯示出與股東的強烈一致。你可以點擊這裏查看他們是否一直在拋售股份。
一般公有制
大衆擁有11%的所有權,主要由個人投資者組成,對海思科製藥集團有一定程度的影響力。這種所有權規模雖然相當可觀,但如果決定與其他大股東不同步,則可能不足以改變公司政策。
後續步驟:
總是值得考慮擁有公司股份的不同羣體。但是,要更好地瞭解海思科製藥集團,我們需要考慮許多其他因素。一個很好的例子:我們發現了 海思科藥業集團的三個警告標誌 你應該知道,其中兩個不應該被忽視。
如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
對這篇文章有反饋嗎?對內容感到擔憂? 取得聯繫 直接和我們聯繫。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是一般性的。 我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章無意提供財務建議。 它不構成買入或賣出任何股票的建議,也沒有考慮您的目標或財務狀況。我們的目標是爲您提供由基本面數據驅動的長期重點分析。請注意,我們的分析可能未將最新的價格敏感型公司公告或定性材料考慮在內。簡而言之,華爾街對上述任何股票都沒有頭寸。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧